Article

Genotypic Correlates of Resistance to the HIV-1 Strand Transfer Integrase Inhibitor Cabotegravir

2022-09-01

Abstract excerpt

<title>Abstract</title> <p><bold><underline>Introduction</underline>:</bold> Cabotegravir (CAB) is an integrase strand transfer inhibitor (INSTI) formulated as a long-acting injectable drug approved for pre-exposure prophylaxis and use with a long acting rilpivirine formulation for maintenance therapy in patients with virological suppression. However, there has been no comprehensive review of the genetic mechanis...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d68271d9-3d8c-5472-80ad-58dc10574baa
DOI: 10.21203/rs.3.rs-2012078/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Genotypic Correlates of Resistance to the HIV-1 Strand Transfer Integrase Inhibitor CabotegravirDOI 10.21203/rs.3.rs-2012078/v1Read

Genotypic correlates of resistance to the HIV-1 strand transfer integrase inhibitor cabotegravir.Semantic proximity Read

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.Semantic proximity Read

Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistanceSemantic proximity Read

Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012.Semantic proximity Read

HIV RNA Screening Reduces Integrase Strand Transfer Inhibitor Resistance Risk in Persons Receiving Long-Acting Cabotegravir for HIV Prevention.Semantic proximity Read

Systematic determination of in vitro phenotypic resistance to HIV-1 integrase strand transfer inhibitors from clinical samplesSemantic proximity Read

HIV drug resistance against strand transfer integrase inhibitors.Semantic proximity Read

Prevalence of Integrase Strand Transfer Inhibitors Resistance Mutations in Integrase Strand Transfer Inhibitors-Naive and -Experienced HIV-1 Infected Patients: A Single Center Experience.Semantic proximity Read

Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profilesSemantic proximity Read

Resistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical Trials of Treatment-Naive PatientsSemantic proximity Read

Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study.Semantic proximity Read

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIVSemantic proximity Read